The world leader in the diagnosis and treatment of heart rhythm disorders, Biosense Webster, is supporting Liryc with a major donation over 3 years to support the scientific chair of excellence in the prevention of sudden cardiac death.

Liryc and Biosense Webster, part of the Johnson & Johnson family, have been collaborating for more than 20 years with a common goal of advancing treatment of cardiac rhythm disorders identifying and developing the diagnostic and treatment tools to optimize patient care. Today, Biosense Webster is reconfirming its confidence in Liryc by making a major donation over 3 years to advance research.

With 350,000 sudden cardiac deaths in Europe and the United States every year, ventricular fibrillation represents a major public health issue. This is why Biosense Webster has decided to fund the chair of Scientific Excellence led by the Professor Michel Haïssaguerre in order to bring rapid advances in the prevention of sudden cardiac death.

This donation illustrates the company’s desire to provide research with the necessary means to make the best possible technology available to healthcare professionals and make a difference in the care and daily life of patients.

Photo credit: © Gautier DUFAU